Literature DB >> 9466315

Targeted gene disruption of murine CD7.

F A Bonilla1, C M Kokron, P Swinton, R S Geha.   

Abstract

CD7 is a 40 kDa type I transmembrane glycoprotein member of the Ig superfamily. CD7 is a marker of mature human T cells and NK cells, and is expressed early in their development. Cross-linking CD7 positively modulates T cell and NK cell activity as measured by calcium fluxes, expression of adhesion molecules, cytokine secretion and proliferation. CD7 associates directly with phosphoinositol 3'-kinase, and CD7 ligation induces production of D-3 phosphoinositides and tyrosine phosphorylation. Severe combined immunodeficiency has been associated with a lack of lymphocyte surface CD7. The CD7 ligand is unknown. The murine CD7 homolog is encoded by a single gene on chromosome 11. In order to characterize the role of CD7 in lymphocyte development and function we have eliminated the CD7 gene by targeted disruption. CD7-deficient mice display normal histology of thymus and spleen, normal lymphocyte populations in primary and secondary lymphoid tissues, and normal serum Ig levels. Specific antibody responses after immunization with T-dependent and T-independent antigens are equivalent in wild-type and CD7 knockout mice. CD7-deficient lymphocytes respond normally to T cell mitogenic and allogeneic stimuli, and display normal NK cell cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9466315     DOI: 10.1093/intimm/9.12.1875

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

Review 1.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

3.  Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Authors:  Yi Tian Png; Natasha Vinanica; Takahiro Kamiya; Noriko Shimasaki; Elaine Coustan-Smith; Dario Campana
Journal:  Blood Adv       Date:  2017-11-21

4.  K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation.

Authors:  Tao Wang; Catherine Huang; Alfonso Lopez-Coral; Kimberly A Slentz-Kesler; Min Xiao; E John Wherry; Russel E Kaufman
Journal:  J Leukoc Biol       Date:  2011-12-19       Impact factor: 4.962

5.  Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression.

Authors:  Kentaro Yomogida; Yuan Chou; Jonathan Pang; Bobby Baravati; Brian J Maniaci; Shili Wu; Yong Zhu; Cong-Qiu Chu
Journal:  Cytokine       Date:  2012-03-10       Impact factor: 3.861

6.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

7.  T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.

Authors:  Kristine E Mayer; Sabine Mall; Nahid Yusufi; Dario Gosmann; Katja Steiger; Lisa Russelli; Henrique de Oliviera Bianchi; Stefan Audehm; Ricarda Wagner; Eva Bräunlein; Anja Stelzl; Florian Bassermann; Wilko Weichert; Wolfgang Weber; Markus Schwaiger; Calogero D'Alessandria; Angela M Krackhardt
Journal:  Theranostics       Date:  2018-11-28       Impact factor: 11.556

8.  An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.

Authors:  Matthew L Cooper; Jaebok Choi; Karl Staser; Julie K Ritchey; Jessica M Devenport; Kayla Eckardt; Michael P Rettig; Bing Wang; Linda G Eissenberg; Armin Ghobadi; Leah N Gehrs; Julie L Prior; Samuel Achilefu; Christopher A Miller; Catrina C Fronick; Julie O'Neal; Feng Gao; David M Weinstock; Alejandro Gutierrez; Robert S Fulton; John F DiPersio
Journal:  Leukemia       Date:  2018-02-20       Impact factor: 11.528

Review 9.  Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

Authors:  Fátima Bayón-Calderón; María L Toribio; Sara González-García
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

10.  CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.

Authors:  Miriam Y Kim; Matthew L Cooper; Miriam T Jacobs; Julie K Ritchey; Julia Hollaway; Todd A Fehniger; John F DiPersio
Journal:  JCI Insight       Date:  2021-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.